Last $10.59 USD
Change Today -0.04 / -0.38%
Volume 517.8K
INO On Other Exchanges
Symbol
Exchange
NYSE Amex
Frankfurt
As of 8:04 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

inovio pharmaceuticals inc (INO) Snapshot

Open
$10.60
Previous Close
$10.63
Day High
$10.74
Day Low
$10.50
52 Week High
02/24/14 - $15.80
52 Week Low
10/31/13 - $6.52
Market Cap
639.6M
Average Volume 10 Days
1.1M
EPS TTM
$-1.34
Shares Outstanding
60.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INOVIO PHARMACEUTICALS INC (INO)

inovio pharmaceuticals inc (INO) Related Bloomberg News

View More Bloomberg News

inovio pharmaceuticals inc (INO) Related Businessweek News

No Related Businessweek News Found

inovio pharmaceuticals inc (INO) Details

Inovio Pharmaceuticals, Inc., together with its subsidiaries, discovers, develops, and develops synthetic vaccines and immune therapies focusing on cancers and infectious diseases. The company’s DNA-based SynCon technology designed to provide protection against known and new unmatched strains of pathogens, such as influenza. Its electroporation DNA delivery technology uses controlled electrical pulses to enhance cellular DNA vaccine uptake. The company’s clinical programs include HPV-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, and malaria vaccines. It is also advancing preclinical research for a seasonal/pandemic influenza vaccine, as well as other products. The company was formerly known as Inovio Biomedical Corporation and changed its name to Inovio Pharmaceuticals, Inc. in May 2010. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Blue Bell, Pennsylvania.

71 Employees
Last Reported Date: 03/17/14
Founded in 1979

inovio pharmaceuticals inc (INO) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $852.8K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $422.0K
Chief Operating Officer
Total Annual Compensation: $409.8K
Chief Medical Officer
Total Annual Compensation: $414.3K
Compensation as of Fiscal Year 2013.

inovio pharmaceuticals inc (INO) Key Developments

Inovio Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Inovio Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. Total revenue was $3.8 million for the three months ended June 30, 2014, compared to $786,000 for the same period in 2013. The loss from operations prior to other income (expenses) for the three months ended June 30, 2014, was $10.2 million, or $0.17 per share compared to $5.7 million, or $0.13 per share for the same period in 2013. The net loss attributable to common stockholders for the three months ended June 30, 2014, was $10.7 million, or $0.19 per diluted share, compared to $10.9 million, or $0.24 per diluted share for the same period in 2013. The increase in revenue for the comparable periods primarily consisted of development fees paid by Roche for work conducted towards partnership with Roche. Total revenue was $6.2 million for the six months ended June 30, 2014, compared to $2.2 million for the same period in 2013. The loss from operations prior to other income (expenses) for the six months ended June 30, 2014, was $20.2 million, or $0.35 per share, compared to $12.3 million, or $0.29 per share, for the same period in 2013. The net loss attributable to common stockholders for the six months ended June 30, 2014, was $21.5 million, or $0.38 per diluted share, compared to $19.7 million, or $0.47 per diluted share, for the same period in 2013. The $0.2 million and $1.8 million increase in net loss attributable to common stockholders for the three and six months ended June 30, 2014, compared with the same periods in 2013 resulted primarily from an increase in R&D and clinical development expenses as well as non-cash stock-based compensation.

Inovio Pharmaceuticals, Inc., Q2 2014 Earnings Call, Aug 11, 2014

Inovio Pharmaceuticals, Inc., Q2 2014 Earnings Call, Aug 11, 2014

Inovio Pharmaceuticals, Inc. Announces Results from Phase II Cervical Dysplasia Trial

Inovio Pharmaceuticals, Inc. announced results from its randomized, double-blind, placebo-controlled phase II trial of VGX-3100 in women with biopsy-proven cervical intraepithelial neoplasia 2/3 (CIN2/3) associated with human papillomavirus (HPV) types 16 or 18. Treatment with VGX-3100, Inovio's HPV16/18-specific immunotherapy, resulted in histopathological regression of CIN2/3 to CIN1 or no disease, meeting the study's primary endpoint. In addition, the trial demonstrated clearance of HPV in conjunction with regression of cervical lesions. Robust T-cell activity was detected in subjects who received VGX-3100 compared to those who received placebo. Treatment was randomized 3:1 between the VGX-3100 and placebo groups, and was stratified by age and severity of CIN. The primary endpoint, histologic regression, was evaluated 36 weeks after the first treatment. In the per protocol analysis, CIN2/3 resolved to CIN1 or no disease in 53 of 107 (49.5%) women treated with VGX-3100 compared to 11 of 36 (30.6%) who received placebo. This difference was statistically significant (p<0.025). Virological clearance of HPV 16 or 18 from the cervix in conjunction with histopathological regression of cervical dysplasia to CIN1 or no disease, a secondary endpoint of the trial, was observed in 43 of 107 (40.2%) VGX-3100 recipients compared to 5 of 35 (14.3%) placebo recipients (p<0.025). As in the phase I study, VGX-3100 elicited robust HPV-specific T cell responses in the majority of treated subjects. A comprehensive analysis of T cell responses is ongoing. The treatment was generally well-tolerated, with only administration site redness occurring significantly more frequently in the VGX-3100 group compared to the placebo group in the 7- and 28-day periods following treatment.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INO:US $10.59 USD -0.04

INO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Dynavax Technologies Corp $1.42 USD +0.04
Peregrine Pharmaceuticals Inc $1.65 USD 0.00
Progenics Pharmaceuticals Inc $5.51 USD +0.21
Vical Inc $1.24 USD 0.00
ZIOPHARM Oncology Inc $3.23 USD +0.08
View Industry Companies
 

Industry Analysis

INO

Industry Average

Valuation INO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 36.7x
Price/Book 5.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 30.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INOVIO PHARMACEUTICALS INC, please visit www.inovio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.